Ana Balañá is a physiotherapist specialized in the respiratory field and especially in neuromuscular patients with ALS. She has and extensive experience of almost 20 years in tertiary hospital centers, treating patients with ALS in multidisciplinary units. At the care level, she is in charge of the adaptation of the home ventilation devices and other secretions’ management devices as well as the education on this field for families and caregivers. She also performs the functional measurements of the respiratory muscles in these patients.
Regarding research in the field of neuromuscular disease, in 2012 the Spanish Society of Pulmonology awarded her a grant to study secretion drainage system for neuromuscular patients and since then the main research’s line has always been physiotherapy in neuromuscular patients. She is actually focusing on the study of respiratory muscle function, and also the study of the ability to cough and management of respiratory complications.
Amylyx Pharmaceuticals Inc is conducting a phase 3 trial to determine the safety and efficacy of their compound ‘AMX0035’ for the treatment of ALS.
Ferrer is conducting a phase 3 trial to evaluate the safety and potential efficacy of an investigational drug for people with Amyotrophic Lateral Sclerosis (ALS).
In the COURAGE-ALS study, we are investigating the efficacy and safety of the drug ‘reldesemtiv’ for the treatment of ALS. This clinical trial is sponsored by Cytokinetics.
In this phase 2 study, we are investigating the safety and efficacy of the drug pegcetacoplan for the treatment of ALS. This trial is sponsored by Apellis Pharmaceuticals.
RT001 in Amyotrophic Lateral Sclerosis
In this phase 2 trial, we will study the safety and efficacy of the compound RT001 in people living with ALS. This clinical trial is sponsored by Retrotope Inc.
This trial will evaluate the efficacy of tauroursodeoxycholic acid (TUDCA) as add-on treatment for people with ALS.